SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Lampertico, Pietro ^{[3
]}

Lim, Young-Suk ^{[4
]}

Agarwal, Kosh ^{[5
]}

Fung, Scott K. ^{[6
]}

Tsang, Owen ^{[7
]}

Elkhashab, Magdy ^{[8
]}

Kao, Jia-Horng ^{[9
]}

Luis Calleja, Jose ^{[10
]}

Khalili, Mandana ^{[11
]}

Ravendhran, Natarajan ^{[12
]}

Tan, Susanna ^{[13
]}

Flaherty, John F. ^{[13
]}

Gaggar, Anuj ^{[13
]}

Lau, Audrey H. ^{[13
]}

Wu, George ^{[13
]}

Hann, Hie-Won L. ^{[14
]}

Pan, Calvin ^{[15
]}

Kim, Hyung Joon ^{[16
]}

Kennedy, Patrick T. F. ^{[17
]}

Chan, Henry Lik Yuen ^{[18
]}

机构：

[1] Hosp Gen Univ Valle Hebron, Barcelona, Spain

[2] Ciberehd, Barcelona, Spain

[3] Univ Milan, Gastroenterol & Hepatol, Fdn Irccs Ca Granda O Maggiore Policlin, Milan, Italy

[4] Univ Ulsan, Dept Gastroenterol, Ctr Liver, Asan Med Ctr,Coll Med, Ulsan, South Korea

[5] Kings Coll Hosp London, Inst Liver Studies, London, England

[6] Univ Hlth Network, Toronto Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada

[7] Princess Margaret Hosp, Kwai Chung, 2-10 Princess Margaret Hosp Rd, Hong Kong, Peoples R China

[8] Toronto Liver Ctr, Res, Toronto, ON, Canada

[9] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan

[10] Hosp Univ Puerta De Hierro, Majadahonda, Spain

[11] Univ Calif San Fransisco, San Francisco, CA USA

[12] Digest Dis Associates, Wyomissing, PA USA

[13] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[14] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

[15] Calvin Q Pan Clin, New York, NY USA

[16] Chung Ang Univ, Coll Med, Seoul, South Korea

[17] Barts Hlth NHS Trust, London, England

[18] Chinese Univ Hong Kong, Hong Kong, Peoples R China

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

476

引用

页码：301A / 301A

页数：1

共 50 条

[41] A Phase 3 Study Comparing Switching: Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 Results
Khalili, Mandana
Lampertico, Pietro
Bae, Ho S.
Ma, Xiaoli
Ramji, Alnoor
Fung, Scott
Ahn, Sang Hoon
Kao, Jia-Horng
Tam, Edward
Halton, Patricia
Yee, Leland
Flaherty, John
Gaggar, Anuj
Liu, Yang
Wu, George
Hann, Hie-Won
Agarwal, Kosh
Lim, Young-Suk
Buti, Maria
Chan, Henry
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S543 - S543
[42] TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS
Buti, M.
Hadziyannis, S.
Mathurin, P.
Urbanek, P.
Sherman, M.
Strasser, S.
Wang, C.
Petersen, J.
Heathcote, E. J.
Marcellin, P.
Sorbel, J.
Mondou, E.
Anderson, J.
Rousseau, F.
JOURNAL OF HEPATOLOGY, 2009, 50 : S10 - S11
[43] A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Week 48 Efficacy and Safety Results
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, G. Mani
Oberle, Corinna
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L. Y.
SWISS MEDICAL WEEKLY, 2019, : 25S - 25S
[44] Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis
Strasser, S. I.
Gane, E. J.
Weilert, F.
Sievert, W.
George, J.
Crawford, D.
Ngu, M. C.
Heathcote, E. J.
Marcellin, P.
Sorbel, J.
Rousseau, F.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A309 - A309
[45] HBEAG LOSS AND SEROCONVERSION PREDICTORS BY BASELINE CLINICAL FEATURES AND VIRAL DEEP SEQUENCING OF TREATMENT WITH TENOFOVIR ALAFENAMIDE FUMARATE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER 144 WEEKS
Ma, Xiaoli
Lim, Young-Suk
Shalimar
Shukla, Akash
Trinh, Huy N.
Andreone, Pietro
Hwang, Jae-Seok
Suri, Vithika
Wu, George
Gaggar, Anuj
Flaherty, John F.
Chow, Wan-Cheng
Marcellin, Patrick
Izumi, Namiki
GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1132
[46] SHORT-TERM (4 WEEKS) SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE (TAF) COMPARED TO TENOFOVIR DISOPROXIL FUMARATE (TDF) AND ENTERCAVIR (ETV) IN TREATMENT-NAIVE ADULT PATIENTS WITH HBV-ACLF FROM SOUTH CHINA
Peng, Liang
Wu, Lina
Zhang, Yeqiong
Zhu, Xiang
Li, Xuejun
Xu, Wenxiong
Zhen, Limin
HEPATOLOGY, 2019, 70 : 311A - 312A
[47] Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis
Buti, Maria
Hadziyannis, Stephanos J.
Mathurin, Philippe
Urbanek, Petr
Sherman, Morris
Strasser, Simone I.
Wang, Chia C.
Petersen, Joerg
Heathcote, Jenny
Marcellin, Patrick
Sorbel, Jeff
Mondou, Elsa
Anderson, Jane
Rousseau, Franck
GASTROENTEROLOGY, 2009, 136 (05) : A865 - A866
[48] Week 96 Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) in Older, HIV-Infected Virologically-Suppressed Adults
Goldstein, D.
Ward, D.
Brinson, C.
Crofoot, G.
Ryu, J.
Haubrich, R.
Sparrow, T. L.
McCallister, S.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S48 - S48
[49] Week 96 Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) in Older, HIV-Infected Treatment-Naive Adults
Ward, D.
Thompson, M.
Goldstein, D.
Brinson, C.
Crofoot, G.
Kinder, C.
Ryu, J.
McNicholl, I.
Haubrich, R.
Weinberg, A.
Sparrow, T. L.
McCallister, S.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S48 - S48
[50] Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF)
Lim, Young-Suk
Ide, Tatsuya
Strasser, Simone I.
Yoon, Ki Tae
Paik, Seung Woon
Flaherty, John F.
Kim, Kyungpil
Gaggar, Anuj
Subramanian, Mani
Mangia, Alessandra
Simon, Krzysztof
Kwan, Peter
Gane, Edward J.
HEPATOLOGY, 2016, 64 : 940A - 940A

← 1 2 3 4 5 →